文献速递先天性心脏病外科

延迟Norwood策略的中期结局

Intermediate-term outcomes of deferred Norwood strategy.
PubMed 文献 · Eur J Cardiothorac Surg · 2022-01-01

本研究回顾性纳入2012至2021年接受延迟Norwood策略的45例左心发育不良综合征及其变异型患者。院内存活者Norwood术后中位随访4.6年,6年无移植生存率84.5%,Fontan完成率不满意,SAVV手术和肺动脉干预需求频繁。

要点

  • 延迟Norwood策略6年无移植生存率为84.5%。
  • Norwood时体重≤2.5 kg是死亡危险因素(HR 11.3,95%CI 1.2-11,P=0.036)。
  • 出生后SAVV反流≥中度是SAVV手术危险因素(HR 16,95%CI 3.6-71,P<0.001)。

核心结论

  • 延迟Norwood策略提供了可接受的中期生存率,但Fontan完成率不满意;SAVV手术和肺动脉干预经常需要。

研究设计与样本

  • 回顾性研究,纳入2012至2021年接受延迟Norwood策略的45例左心发育不良综合征及其变异型患者。
  • 延迟Norwood策略指常规双侧肺动脉环缩和导管支架置入或持续前列腺素E1给药后计划性Norwood手术。
  • 院内存活者Norwood术后中位随访4.6年(四分位距1.9,6.8)。

主要发现

  • 14例(31.1%)无危险因素;Norwood时中位年龄1.8个月(0.9,3.5),中位体重3.1 kg(2.7,3.6)。
  • 6年无移植生存率84.5%;出生体重≤2.5 kg和出生后SAVV反流≥中度不是死亡危险因素;Norwood时体重≤2.5 kg是死亡危险因素(HR 11.3,95%CI 1.2-11,P=0.036)。
  • 22例(48.9%)完成Fontan且无死亡,7例(15.5%)等待Fontan;5年免于SAVV手术率53.1%。
  • 出生后SAVV反流≥中度是SAVV手术危险因素(HR 16,95%CI 3.6-71,P<0.001);导管支架置入对SAVV手术有保护作用(HR 0.09,95%CI 0.01-0.68,P=0.019)。
  • 3年免于外科和导管肺动脉干预率27.1%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to assess outcomes of the deferred Norwood strategy, i.e. planned Norwood following routine bilateral pulmonary artery banding and ductal stenting or continuous prostaglandin E1 administration. METHODS: Forty-five patients with hypoplastic left heart syndrome and its variants treated with the deferred Norwood strategy between 2012 and 2021 were enrolled. Mid-term outcomes were retrospectively reviewed. The median follow-up period after Norwood in hospital survivors was 4.6 years (interquartile range: 1.9, 6.8). RESULTS: Fourteen patients (31.1%) had no risk factors. The median age and weight at Norwood were 1.8 months (0.9, 3.5) and 3.1 kg (2.7, 3.6). Transplant-free survival at 6 years was 84.5%. Birth weight ≤2.5 kg and systemic atrioventricular valve (SAVV) regurgitation ≥ moderate after birth were not risk factors for mortality; body weight at Norwood ≤2.5 kg, however, was a risk factor [hazard ratio (HR), 11.3; 95% confidence interval (CI), 1.2-11; P = 0.036]. Twenty-two (48.9%) underwent Fontan with no mortalities, and 7 (15.5%) are awaiting Fontan. Freedom from SAVV surgery at 5 years was 53.1%. SAVV regurgitation ≥ moderate after birth was a risk factor for SAVV surgery (HR, 16; 95% CI, 3.6-71; P < 0.001); however, ductal stenting had a protective effect against SAVV surgery (HR, 0.09; 95% CI, 0.01-0.68; P = 0.019). Freedom from both surgical and catheter-based pulmonary artery intervention at 3 years was 27.1. CONCLUSIONS: Although deferred Norwood provided acceptable intermediate-term survival, the Fontan completion rate was unsatisfactory. SAVV surgery and pulmonary artery intervention were frequently required.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Hoashi T, Imai K, Okuda N, et al. Intermediate-term outcomes of deferred Norwood strategy. Eur J Cardiothorac Surg. 2022. PMID: 35178578. doi:10.1093/ejcts/ezac099

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。